Gaining Insight into Mitochondrial Targeting: AUTAC-Biguanide as an Anticancer Agent
Open Access
Abstract
AUTAC-Biguanide is a hybrid compound designed to target mitochondria, inducing their degradation by mitophagy. This study unveils the potential of biguanides as cancer cell-targeting agents, emphasizing AUTAC-Biguanide’s superior antiproliferative properties compared to metformin and its selectivity for cancer cells. The mechanism behind this heightened effect includes the ability of AUTAC-Biguanide to trigger mitophagy. By providing a comprehensive analysis of these findings, this study adds valuable insights to the field of mitochondrial-targeting anticancer agents.Keywords
All Related Versions
Funding Information
- Natural Sciences and Engineering Research Council of Canada (RGPIN-2021-03128)
This publication has 30 references indexed in Scilit:
- Biguanides drugs: Past success stories and promising future for drug discoveryEuropean Journal of Medicinal Chemistry, 2021
- A Novel Triphenylphosphonium Carrier to Target Mitochondria without Uncoupling Oxidative PhosphorylationJournal of Medicinal Chemistry, 2021
- Emerging New Concepts of Degrader TechnologiesTrends in Pharmacological Sciences, 2020
- AUTACs: Cargo-Specific Degraders Using Selective AutophagyMolecular Cell, 2019
- Teaching the basics of autophagy and mitophagy to redox biologists—Mechanisms and experimental approachesRedox Biology, 2015
- Endogenous Nitrated Nucleotide Is a Key Mediator of Autophagy and Innate Defense against BacteriaMolecular Cell, 2013
- Mitochondrial accumulation of a lipophilic cation conjugated to an ionisable group depends on membrane potential, pH gradient and pK a: implications for the design of mitochondrial probes and therapiesJournal of Bioenergetics and Biomembranes, 2012
- Measurement of Autophagy in Cells and Tissues2010
- Targeting lipophilic cations to mitochondriaBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2008
- LC3 and Autophagy2008